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Introduction
Streptococcus pneumoniae (S. pneumoniae) is the most 
common cause of community acquired pneumonia (CAP) in 
adults accounting for most cases of pneumonia hospitalizations 
and deaths [1-2]. Bacteremic pneumonia is the most frequent 
invasive pneumococcal disease (IPD) in adults and remains a 
major cause of morbidity and mortality despite improvements in 
medical care [2-3]. From older and recent studies, it is estimated 
that approximately 20% of patients with pneumococcal 
pneumonia develop bacteremia [3-4], with a mortality rate 
ranging between 15-35%.
More than 50% of S. pneumoniae bacteremia cases occur in 
elderly patients and most studies show increased pneumococcal-
related deaths in this population [1-3-5]. Variations between 
reported fatality rates might be explained by differences between 
studied populations including demographic factors, underlying 
health conditions, severity of illness at the time of admission, 
and bacterial factors. Also, geographical and temporal situations 
should be considered. On the other hand, 
drug resistance does not appear to contribute to mortality or 
ICU admission rates [5].
Despite the fact that BPP is a frequent and severe disease, there 
is minimal information regarding BPP in our city. We report 
here the result of 26-year prospective study in patients with BPP 
treated in our hospital, to assess local disease incidence, clinical, 
radiographic and microbiological features, as well as to evaluate 
factors related to mortality.
Methods
Study Design and Study Population
This was a longitudinal, prospective observational study  of 
adult patients with BPP evaluated at the Santamarina Hospital 
in the city of Tandil. The hospital is a 130-bed primary care 
community hospital. Tandil is a city with a population of 
130,000 inhabitants located in the province of Buenos Aires, 
Argentina.
Inclusion/exclusion criteria
Inclusion criteria: Patients 18 years or older with BPP that were 
assisted in the emergency room and admitted to the hospital or 
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treated in ambulatory setting between 1989 and 2015.
Exclusion criteria: having been hospitalized in the last 30 days, 
or presented with any other evidence suggestive of nosocomial 
pneumonia, severe immunosuppression such in transplantation, 
AIDS or receiving chemotherapy or other immunosuppressive 
drugs.
Study definitions/variables
Pneumonia was defined as the presence of a new infiltrate on 
chest radiograph plus two or more of the following clinical 
manifestations including: fever (axillary temperature >37.8ºC), 
cough, production of purulent sputum, pleuritic chest pain and 
dyspnoea. BPP was defined as a diagnosis of pneumonia with 
one or more positive blood cultures for S. pneumoniae.
Identification of patients with BPP: one of the authors of this 
manuscript, (CH or JG), or a resident, reviewed admissions to 
the hospital daily, including holidays. The laboratory informed 
as soon as possible, when S. pneumoniae was isolated from blood 
culture.  Data of chart was reviewed and a form was completed 
within 48-72h of admission. All patients were questioned, 
examined and followed exclusively by the authors. (JG or CH).
When a patient with criteria of BPP was not admitted and sent 
home we strived to contact him in order to assist and include 
him in the study.
Hospital based incidence was calculated dividing number of 
BPP/adult patients admitted annually to the hospital x 1000. 
Seasonal distribution was registered. Population incidence, was 
calculated during the period 2010- 2015, adding to our series of 
patients with BPP admitted to the other two centres of the city, 
and considering population variations in the period.
The following variables were recorded on admission directly 
from the subject, or from documentation in chart or interview 
with relatives: age, sex, duration of illness before consult, 
underlying chronic conditions such as diabetes, chronic renal 
failure, congestive heart failure, chronic lung disease, neurologic 
disease, malignancies, HIV infection, alcoholism, hepatic 
disease, smoking, prior antimicrobial therapy as well as clinical 
signs and symptoms. Living in nursing home or   homelessness 
was registered too.
Patients with dull percussion and bronchial breathing sounds on 
auscultation were considered as having clinical consolidation.
Hypotension was defined as systolic arterial tension below 
90mmHg. Abdominal pain, vomiting, hypotension, and 
confusion were considered nonpulmonary symptoms.
Classical pneumococcal infection was considered if patients 
had all four of the following features: fever, pleuritic chest pain, 
lobar consolidation on chest X ray and leucocytosis. Pleural fluid 
examination was performed in all patients with pleural effusion. 
Empyema was considered when macroscopic pus or bacteria 
were identified in pleural fluid.
History of pneumococcal vaccination was recorded in all cases 
and considered positive in patients who had received at least a 
single dose of 23-valent pneumococcal polysaccharide vaccine 
within the last 5 years. On admission, patients were stratified 
into risk classes I to V based on Pneumonia Severity Index (PSI) 
score [6].
Laboratory
Leukocytosis was considered when white blood cells were more 
than 12,000/ml and leukopenia when WBC <4,000/ml
Microbiological Testing
S. pneumoniae was identified using standard microbiology 
procedures. One set of blood cultures were collected from 
each patient at entry, which is considered standard of care for 
patients with CAP admitted to the hospital.
Conventional broth culture using nutritionally enriched media 
was used until 1997, after which fully automated, continuous 
blood culture monitoring equipment (BacT/ALERT® 3D 
BioMérieux, Inc. 100 Rodolphe Street, Durham, NC) became 
available. High quality sputum specimens (containing <10 
squamous epithelial cells and >25 Polymorph Nuclear cells per 
low power field) were processed for bacterial diagnosis. Briefly, 
sputum was homogenized in 1.2 ml of sterile saline, spread onto 
a glass slide, air dried and heat fixed. Strains were identified 
based on Gram stains and morphology: gram-positive cocci 
found in singles, in pairs or in short chains were indicative of 
pneumococci infection. Sputum samples were inoculated on 
blood agar and chocolate agar plates and incubated at 35ºC 
with 5-10% CO2 for 72 hours. All S. pneumoniae isolates were 
tested for penicillin susceptibility by diffusion, using 1 µg 
oxacillin disks and by broth micro-dilution test. Isolates were 
also screened for susceptibility to erythromycin, tetracycline, 
and levofloxacin using disk diffusion method. In addition, 
minimum inhibitory concentration (MIC) tests were used to 
determine susceptibility to erythromycin, extended spectrum 
cephalosporins, fluoroquinolones, tetracycline, trimethoprim 
sulfametoxazol, clindamycin, cefuroxime and vancomycin, 
in accordance to Clinical and Laboratory Standards Institute 
(CLSI, 2012) established guidelines [7].
Radiology
Images on chest radiograph were classified by one of the 
investigators (JG) according to pattern (lobar consolidation, 
interstitial infiltrate, bronchopneumonia, pleural effusion) and 
extension (number of lobes affected, bilateral involvement)
Outcome
Patient were followed for 30 days after diagnosis, and 
complications were recorded, namely: pleural effusion, 
empyema, admission to ICU and need of mechanical ventilation. 
Overall case fatality rate was defined as death due to any 
cause within 30 days of hospitalization. Overall case fatality 
rate was defined as death due to any cause within 30 days of 
hospitalization.
Statistical Analysis 
Qualitative variables are presented as the mean and range(min-
max), while categorical variables are presented as frequency and 
percent. Contingency tables were used to measure associations 
with calculation of the chi-squared or Fisher’s exact test, and 
odds ratio (OR) were estimated. Multiple logistic regression 
analyses was performed to evaluate those factors found to be 
significant by univariate analysis and previously hypothesized 
to affect mortality. Two-tailed p-values are reported, with 
statistical significance when p<0.05. SAS V9.3 statistical 
software was used for calculations (SAS, Institute Inc. Cary, NC, 
USA). 
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Results
Epidemiology: 279 patients were included. Distribution of cases 
showed a sporadic pattern along the study ranging from 3 to 30 
cases per year Figure 1. A decrease of 50% was observed in the 
last two years of the study. Hospital-based incidence of BPP was 
2.1 cases/1,000 admissions and population-based incidence 
was 11.8 per 100,000 person-years (95% CI, 11.65-12.01), while 
38% of episodes occurred in winter. The mean time from onset 
of illness to hospital admission was 2.9 days (1.15).
Two patients, the only individuals who had received 
antipneumococcal vaccine, both with humoral immunodeficiency 
multiple myeloma and hypogammaglobulinemia, had recurrent 
episodes of BPP.
The main demographic, comorbidities, clinical findings, 
radiographic, laboratory, severity and outcome features of 
patients are showed in Table 1A and Table1B.
Table 1A Main characteristics of study population. Differences between 
survivors and mortalities by univariate analysis. 
Table 1B Patient characteristics of study population. Differences between 
survivors and mortalities by univariate analysis.
 
The classic association of fever, chest pain, leukocytosis and 
lobar consolidation was present in 35 patients (14%), all of 
whom survived. 
Non-pulmonary symptoms as abdominal pain, confusion and 
hypotension were present in 50% of cases. In 3 cases there was 
associated meningitis, and in one case purulent pericarditis.
Antibiotic treatment: Ninety five percent of BPP cases admitted 
to the hospital received monotherapy and 5% combined 
therapy. Fifteen patients were managed as outpatients, and 
treated with oral antibiotics as amoxicillin, clarithromycin, 
and fluoroquinolones, or intramuscular ceftriaxone. βeta-
lactam antibiotics (cefotaxime, ceftriaxone, ampicillin, ampi/
sulbactam) were used in 93% of patients.
Mortality: 49 patients died, resulting in an overall mortality rate 
of 16.7%: 27 deaths (55%) occurred within the first 3 days of 
hospitalization. Mean time elapsed between hospital admission 
and death was 5.2 days (median time 3 days) and there was an 
increment of death with age. Factors found to be significantly 
associated with mortality in univariate analyses were: age 
>80 years, dyspnea, hypotension, confusion, nonpulmonary 
symptoms, bilateral and diffuse infiltrates on chest radiograph, 
leukopenia, and high PSI score. Conversely, fever, chest pain 
and lobar infiltrates were significant predictors of survival. 
Multivariate analysis is shown in Table 2.
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Figure 1 Number of cases of BPP between 1989-2015 (n=279)
 
 Study Population Survivors Mortalities Pvalue 
Total number of 
patients 279 230 49  
Demographics 
Mean age 59.7 SD+18.42    
18-50 76(27.24) 70(92.1) 6(7.89)  
50-65 81(29.03) 68(83.9) 13(16)  
65-80 83(29.74) 69(83.1) 14(16.8)  
>80 39(13.9) 23(58.9) 16(41) <0.0001 
Males/females 177    
Females 102    
Comorbidities 
One or more 180(64.5) 144 (62.61) 36(73.47) 0.1491 
Cigarette smoking 75(26.8) 64(27.83) 11(22.45) 0.44 
COPD 51(18.09) 13(5.65) 38(77.55) 0.0998 
CHF 47(16.85) 15(6.52) 32(65.31) 0.0046 
Alcoholism 44(15.77) 5(2.17) 39(79.59) 0.2390 
Diabetes 28(10.04) 3(1.30) 25(51.02) 0.4353* 
Liver disease 21(7.53) 4(1.74) 17(34.69) 0.0771* 
Malignancy 20(7.17) 5(2.17) 15(30.61) 0.3635* 
Neurologic disease 19(6.91) 5(2.17) 14(28.57) 0.3451* 
Renal failure 9(3.23) 3(1.30) 6(12.24) 0.1970* 
HIV infection 5(1.79) 4(1.73) 1(2.04)  
Physical Examination 
Fever 212(75.99) 186(80.8) 26(53) <0.0001 
Cough 158(56.63) 139(60.4) 19(38.7) 0.005 
Dyspnoea 140(50.8) 98(42.6) 42(85.7) 0.0001 
Chest pain 114(40.86) 106(46) 8(16.3) 0.0001 
Consolidation 105(37.6) 94(40.8) 11(22.4) 0.01 
Expectoration 79(28.32) 70(30.4) 9(18.3) 0.08 
Hypotension 79(28.3) 56(24.3) 23(46.9) 0.0015 
Confusion 55(19.7) 34(14.7) 21(42.8) <0.0001 
Abdominal Symptoms 59(17.9) 43(24.7) 7(14.2) 0.26 
Non-pulmonary 
Symptoms 139(50) 108(47) 31(43) 0.0131 
Fisher Exact test*  




 Study Population Survivors Moratlities Pvalue 
Total number of patients 279 230 49  
Radiographic findings 
Unilateral infiltrate 209(74.91) 178(77.39) 31(63.26) 0.0384 
Bilateral infiltrate 56(24.35) 40(17.39) 16(41.02) 0.0154 
Lobar 160(57.34) 143(62.17) 17(34.69) 0.0006 
Diffuse 102(36.55) 76(33.04) 26(53.06) 0.0057 
Pleural effusion 49(17.56) 40(17.39) 9(18.36) 0.8705 
Laboratory 
Mean Hematocrit 37.7(16-59)    
White blood cells 16800 (900-44700) 17276 13247  
Leukocytosis 177(63.44) 156(67.82) 21(42.85) 0.0010 
Leukopenia 28(10.03) 14(6.08) 14(28.57) <0.0001 
Severity 
PSI Score I 47 (16.84)    
PSI Score II 71(25.44)    
PSI Score III 60(21.5)    
PSI Score IV 94(33.69)    
PSI Score V 7(2.5)    
PSI Score I-II-III 178(63.7) 167(72.6) 11(22.4) <0.0001 
PSI Score IV+V 101(36.2) 52(22.60) 38(77.55) <0.0001 
Complications 
ICU admission 60(21.50) 32(13.9) 28(57.14) <0.0001 
Mechanical Ventilation 40(14.33) 14(6.08) 26(53.06) <0.001 
Empyema 21(7.52) 18(7.82) 3(6.12) 0.707 
 
Table 2 Multivariate analysis of variables potentially associated with 
mortality
Microbiology: All pneumococcal strains were found to be 
susceptible to penicillin (MIC=0.006-2 µg/ml) and ceftriaxone 
(MIC =0.012 to 0.019 µg/ml). Percentages of resistance to other 
antibiotics were: erythromycin 8.1% (MIC =0.064 – 256 µg/ml), 
clindamycin 6.4% (MIC= 0.024-128 µg/ml), doxycycline 6.9% 
(MIC=0.5-64.0 µg/ml). Resistance rate to fluoroquinolones 
(levofloxacin) remained low 2.8% (MIC=0.38-8.00 µg/ml). 
Only 4 patients had S. pneumoniae isolated simultaneously 
in sputum and blood. One case of BPP and simultaneous 
pulmonary tuberculosis was detected.
Discussion
In this study of 279 patients with bacteremic pneumococcal 
pneumonia we confirm a considerable early mortality associated 
to increased age and increased severity of disease at time of 
presentation. 
Overall annual rate of BPP in this study population was 
11.8 cases/100,000 person-years, which is in agreement with 
other published results [8-10].  The reduction in the last two 
years could be secondary to herd effect of PVC 13, a vaccine that 
is mandatory in children in our city since 2012. The average age 
of 60 years found for the patients in our study is comparable to 
the mean age in other studies (range between 52 and 64 years 
old)[5,8,11]. 
Regarding underlying conditions and in agreement with 
previous published results, cigarette smoking, was the most 
prevalent risk factor, followed by chronic obstructive lung 
disease and congestive heart failure [10,12,13]. In fact, current 
cigarette smoking was predictive of BPP in one study [8] and 
was associated to septic shock in another [14].
Interestingly, one third of the patients had no evidence of any 
predisposing condition for BPP. We believe that this group 
deserves to be exhaustively evaluated in order to gain knowledge 
in the prevention of IPD. 
Clinical manifestations were similar to those reported in the 
literature [12,15], except for sputum production which was 
less frequent: only 30% of the patients with BPP presented 
this symptom and this fact has been observed by others 
[16,17]. Isolation of S. pneumoniae from sputum specimens 
was very uncommon in our population. This can be related to 
early hospital admission or to differences in BPP and non-BPP 
pathophysiology [18]. 
Classical presentation with fever, chest pain, leukocytosis 
and lobar pattern on chest radiograph, although uncommon, 
showed significant correlation to better outcome.
Almost half of the patients had   nonpulmonary symptoms from 
onset, so it is important to consider hemodynamic, abdominal 
or neurological manifestations in patients at risk for IPD in 
order to ensure prompt diagnosis and treatment [19]. 
As has been previously described most patients with BPP 
presented marked leukocytosis and neutrophilia. Leukopenia, 
although less frequent, was significantly related to worst 
outcome, as others investigators have observed [18,20]. 
In agreement with already published large series of patients 
[5,21,22] the presence of bacteremia was not associated with 
severity of illness, since most patients presented low PSI score 
(classes I-III). Even though the PSI score was not originally 
designed as a prognostic tool for BPP, it can be used to define 
illness severity because, although less specific, it is still more 
sensitive than other scores for BPP-related risk of death [23]. 
Surprisingly, patients in the low score risk group had higher than 
expected mortality rate. These were mainly young individuals, 
with specific comorbidities not identified by the PSI score such 
as asthma, COPD; HIV infection, obesity, alcohol and tobacco 
use. As some experts have reported, mortality within a certain 
score stratum may differ depending on the patient group [23]. 
It is possible that pneumococcal disease by itself may differ in 
previously healthy patients compared to those who present an 
underlying condition.
Main complications overlapped with those frequently observed 
in patients with CAP admitted to hospital, namely: ICU stay, 
presence of pleural effusion, empyema and need for mechanical 
ventilation [5]. 
Mortality rate was 17%, similar to the results obtained by others 
in larger series [5,11,13] and most deaths (55%) occurred within 
the first 3 days after hospital admission as already has been 
described [4,5]. In our study, severity of disease at onset was 
the most important factor associated with death. The presence 
of severe symptoms such as dyspnea, hypotension or altered 
mental status, may suggest organ dysfunction, indicating early 
signs of sepsis. As others have observed, age was found to be an 
important marker of poor prognosis, mostly in patients over 80 
years of age [5,24].
Penicillin resistance is not a problem in our region, so we can 
continue using βeta-lactams, alone or combined for treatment 
of BPP.
This study has several limitations. The study was performed 
in a single center, in a small city then generalizibility of this 
data may be limited. Since the study was performed during a 
prolonged period of time, the local pactice for therapy of BPP 
may have changed and affected the clinical outcomes. In this 
study S. pneumoniae serotyping was not performed.
In conclusion we found that BPP is a common infection with a 
considerable mortality, mostly after the first days of onset of the 
disease.  Deaths were associated with increased age, increased 
severity of disease at onset and leukopenia.
We believe that a large-scale collaborative epidemiological 
study is needed in the region to gain further insight related to 
circulating pneumococcal strains.  This knowledge would allow 
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Factor OR (95% CI) P 
Fever 0.292 (0.13-0.66) 0.0033 
Chest pain 0.3619 (0.13-0.95) 0.04 
Age of >80 years 4.03 (1.55-10.49) 0.0042 
Confusion 5.43 (2.24-13.19) 0.0002 
Leukopenia 6.27 (2.24-18.38) 0.0008 
Dyspnea 8.58 (3.20-23.04) <0.0001 
us to improve the use of available pneumococcal vaccines.   We 
must not forget that surveillance strategies focusing on BPP, 
underestimate pneumococcal disease burden and hence the true 
benefits of pneumococcal immunization in adults.
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